Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91


Oxaloacetate Protects Rat Liver From Experimental Warm Ischemia/Reperfusion Injury by Improving Cellular Energy Metabolism.

Merlen G, Raymond VA, Cassim S, Lapierre P, Bilodeau M.

Liver Transpl. 2019 Apr;25(4):627-639. doi: 10.1002/lt.25415. Epub 2019 Mar 1.


Effects of perioperative fluid management on postoperative outcomes in liver transplantation: a systematic review protocol.

Carrier FM, Chassé M, Wang HT, Aslanian P, Bilodeau M, Turgeon AF.

Syst Rev. 2018 Oct 31;7(1):180. doi: 10.1186/s13643-018-0841-3.


Type 3 cytokines IL-17A and IL-22 drive TGF-β-dependent liver fibrosis.

Fabre T, Molina MF, Soucy G, Goulet JP, Willems B, Villeneuve JP, Bilodeau M, Shoukry NH.

Sci Immunol. 2018 Oct 26;3(28). pii: eaar7754. doi: 10.1126/sciimmunol.aar7754.


Survival associated with cerebrospinal fluid analysis in downer adult dairy cows: A retrospective study (2006-2014).

Bilodeau MÈ, Achard D, Francoz D, Grimes C, Desrochers A, Nichols S, Babkine M, Fecteau G.

J Vet Intern Med. 2018 Sep;32(5):1780-1786. doi: 10.1111/jvim.15305. Epub 2018 Sep 14.


Metabolite profiling identifies a signature of tumorigenicity in hepatocellular carcinoma.

Cassim S, Raymond VA, Lacoste B, Lapierre P, Bilodeau M.

Oncotarget. 2018 Jun 1;9(42):26868-26883. doi: 10.18632/oncotarget.25525. eCollection 2018 Jun 1.


Upregulation of Krebs cycle and anaerobic glycolysis activity early after onset of liver ischemia.

Chan TS, Cassim S, Raymond VA, Gottschalk S, Merlen G, Zwingmann C, Lapierre P, Darby P, Mazer CD, Bilodeau M.

PLoS One. 2018 Jun 14;13(6):e0199177. doi: 10.1371/journal.pone.0199177. eCollection 2018.


The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.

Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver.

CMAJ. 2018 Jun 4;190(22):E677-E687. doi: 10.1503/cmaj.170453. No abstract available.


Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience.

Al-Judaibi B, Thomas B, Wong P, Benmassaoud A, Chen JH, Dokus MK, Hussaini T, Bilodeau M, Burak KW, Marotta P, Yoshida EM.

Ann Hepatol. 2018 May-June;17(3):437-443. doi: 10.5604/01.3001.0011.7388. Epub 2018 Apr 9.


Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment.

Cassim S, Raymond VA, Dehbidi-Assadzadeh L, Lapierre P, Bilodeau M.

Cell Cycle. 2018;17(7):903-916. doi: 10.1080/15384101.2018.1460023. Epub 2018 May 21.


Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.

Faisal N, Bilodeau M, Aljudaibi B, Hirch G, Yoshida EM, Hussaini T, Ghali MP, Congly SE, Ma MM, Lilly LB.

Exp Clin Transplant. 2019 Feb;17(1):59-63. doi: 10.6002/ect.2017.0201. Epub 2018 Apr 4.


Successful Liver Transplants for Liver Failure Associated With Pyruvate Kinase Deficiency.

Chartier ME, Hart L, Paganelli M, Ahmed N, Bilodeau M, Alvarez F.

Pediatrics. 2018 Apr;141(Suppl 5):S385-S389. doi: 10.1542/peds.2016-3896.


From in vivo to in vitro: Major metabolic alterations take place in hepatocytes during and following isolation.

Cassim S, Raymond VA, Lapierre P, Bilodeau M.

PLoS One. 2017 Dec 28;12(12):e0190366. doi: 10.1371/journal.pone.0190366. eCollection 2017.


Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β.

Hart KM, Fabre T, Sciurba JC, Gieseck RL 3rd, Borthwick LA, Vannella KM, Acciani TH, de Queiroz Prado R, Thompson RW, White S, Soucy G, Bilodeau M, Ramalingam TR, Arron JR, Shoukry NH, Wynn TA.

Sci Transl Med. 2017 Jun 28;9(396). pii: eaal3694. doi: 10.1126/scitranslmed.aal3694.


Reply to: "Proposal of a novel MELD exception point system for hepatocellular carcinoma: Dynamics better than tumor characteristics?"

Bhat M, Ghali P, Bilodeau M.

J Hepatol. 2017 Jul;67(1):199-200. doi: 10.1016/j.jhep.2017.03.019. Epub 2017 Mar 24. No abstract available.


Novel Immunotherapies for Autoimmune Hepatitis.

Cassim S, Bilodeau M, Vincent C, Lapierre P.

Front Pediatr. 2017 Jan 26;5:8. doi: 10.3389/fped.2017.00008. eCollection 2017. Review.


Highly tumorigenic hepatocellular carcinoma cell line with cancer stem cell-like properties.

Lacoste B, Raymond VA, Cassim S, Lapierre P, Bilodeau M.

PLoS One. 2017 Feb 2;12(2):e0171215. doi: 10.1371/journal.pone.0171215. eCollection 2017.


Protection against Acute Hepatocellular Injury Afforded by Liver Fibrosis Is Independent of T Lymphocytes.

Lacoste B, Raymond VA, Lapierre P, Bilodeau M.

PLoS One. 2016 Oct 28;11(10):e0165360. doi: 10.1371/journal.pone.0165360. eCollection 2016.


Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.

Bhat M, Ghali P, Dupont B, Hilzenrat R, Tazari M, Roy A, Chaudhury P, Alvarez F, Carrier M, Bilodeau M.

J Hepatol. 2017 Feb;66(2):374-381. doi: 10.1016/j.jhep.2016.10.008. Epub 2016 Oct 15.


Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.

Faisal N, Bilodeau M, Aljudaibi B, Hirsch G, Yoshida EM, Hussaini T, Ghali MP, Congly SE, Ma MM, Leonard J, Cooper C, Peltekian K, Renner EL, Lilly LB.

Transplantation. 2016 May;100(5):1059-65. doi: 10.1097/TP.0000000000001126.


The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.

MacParland SA, Bilodeau M, Grebely J, Bruneau J, Cooper C, Klein M, Sagan S, Choucha N, Balfour L, Bialystok F, Krajden M, Raven J, Roberts E, Russell R, Houghton M, Tyrrell DL, Feld JJ; National CIHR Research Training Program in Hepatitis C.

Can J Gastroenterol Hepatol. 2014 Oct;28(9):481-7.

Supplemental Content

Loading ...
Support Center